2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neoplasms
15
Papillomavirus Infections
9
Uterine Cervical Neoplasms
7
Pancreatic Neoplasms
6
Breast Neoplasms
6
Ovarian Neoplasms
5
Prostatic Neoplasms
4
Neuroendocrine Tumors
4
Neoplasm Metastasis
4
Myasthenia Gravis
3
Multiple Myeloma
3
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Autoimmune Diseases
3
Thyroid Diseases
2
Pancreatic Cyst
2
Neuroblastoma
2
Mesothelioma, Malignant
2
Lymphoma, Non-Hodgkin
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Hairy Cell
2
Leukemia
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
COVID-19
2
Brain Neoplasms
2
Abortion, Spontaneous
2
Interventions
Pemetrexed
40
Cisplatin
35
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Drug Therapy
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Oxaliplatin
3
Imatinib Mesylate
3
Fluorouracil
3
Cerebral Decortication
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
Data Collection
×
Clear all
NCT05308966
2025-10-06
MESO-IMMUNE
Groupe Francais De Pneumo-Cancerologie
Completed
204 enrolled